Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/162044
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Castelo-Branco Flores, Camil | - |
dc.contributor.author | Cancelo Hidalgo, M. J. | - |
dc.contributor.author | Palacios Ruiz, Lucas Santiago | - |
dc.contributor.author | Ciria Recasens, M. | - |
dc.contributor.author | Fernández Pareja, A. | - |
dc.contributor.author | Carbonell Abella, Cristina | - |
dc.contributor.author | Manasanch, J. | - |
dc.contributor.author | Haya Palazuelos, J. | - |
dc.date.accessioned | 2020-05-22T12:36:23Z | - |
dc.date.available | 2020-05-22T12:36:23Z | - |
dc.date.issued | 2019-11-21 | - |
dc.identifier.issn | 1369-7137 | - |
dc.identifier.uri | http://hdl.handle.net/2445/162044 | - |
dc.description.abstract | Objective: This study aimed to compare the efficacy and safety of ossein-hydroxyapatite complex (OHC) versus calcium carbonate (CC) for preventing bone loss during perimenopause in current clinical practice.Methods: The prospective, comparative, non-randomized, open-label study included 851 perimenopausal women with basal bone mineral density (BMD) T-score ≥-2 standard deviations (SDs). Participants received either OHC (712 mg calcium/day) or CC (1000 mg calcium/day) over 3 years. BMD was evaluated by dual-energy X-ray absorptiometry at the lumbar spine (L2-L4) at baseline and after 18 and 36 months of follow-up. Adverse drug reactions (ADRs) were also recorded.Results: In women receiving OHC, BMD at the L2-L4 site remained stable over the 3-year follow-up period (mean [SD] change 0.00 [0.11] g/cm2). BMD in the CC arm decreased -3.1% (mean [SD] - 0.03 [0.11] g/cm2). Between-group differences were statistically significant (p < 0.001) and favored OHC. ADRs were more frequent in the CC group (7.7% vs. 2.7% in the OHC group; p = 0.001), affecting primarily the gastrointestinal system.Conclusion: OHC showed greater efficacy and tolerability than CC for bone loss prevention in perimenopausal women in real-world practice. As the daily dose of calcium was higher in the CC group, the differences might be linked to the ossein compound in OHC. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Taylor and Francis | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1080/13697137.2019.1685488 | - |
dc.relation.ispartof | Climacteric, 2020, vol. 23, num. 3, p. 252-258 | - |
dc.relation.uri | https://doi.org/10.1080/13697137.2019.1685488 | - |
dc.rights | (c) The Author(s), 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) | - |
dc.subject.classification | Menopausa | - |
dc.subject.classification | Densitometria òssia | - |
dc.subject.classification | Osteoporosi | - |
dc.subject.other | Menopause | - |
dc.subject.other | Bone densitometry | - |
dc.subject.other | Osteoporosis | - |
dc.title | Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss | - |
dc.type | info:eu-repo/semantics/article | - |
dc.identifier.idgrec | 697733 | - |
dc.date.updated | 2020-05-22T12:36:23Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31747785 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
697733.pdf | 1.6 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License